Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.

2015

Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.
Erlandson KM, Taejaroenkul S, Smeaton L, et al. "A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings." Open Forum Infect Dis. 2015;2(3):ofv095.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.
Tashima KT, Mollan KR, Na L, et al. "Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity." HIV Clin Trials. 2015;16(4):147-56.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, et al. "Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia." Open Forum Infect Dis. 2015;2(3):ofv085.
Paris RM, Petrovas C, Ferrando-Martinez S, et al. "Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression." PLoS ONE. 2015;10(12):e0144767.
Ouyang Z, Buzon MJ, Zheng L, et al. "Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir." Open Forum Infect Dis. 2015;2(2):ofv045.
Cillo AR, Hilldorfer BB, Lalama CM, et al. "Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery." AIDS. 2015;29(16):2121-9.
Overton ETurner, Chan ES, Brown TT, et al. "Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial." Ann. Intern. Med.. 2015;162(12):815-24.

2014

Havers F, Smeaton L, Gupte N, et al. "25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings." J. Infect. Dis.. 2014;210(2):244-53.
Zheng Y, Hughes MD, Lockman S, et al. "Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens." Clin. Infect. Dis.. 2014;59(6):888-96.
Mollan KR, Smurzynski M, Eron JJ, et al. "Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data." Ann. Intern. Med.. 2014;161(1):1-10.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
McKinnon JE, Mailliard RB, Swindells S, et al. "Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)." PLoS ONE. 2014;9(5):e95524.
Shaffer D, Hughes MD, Sawe F, et al. "Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)." J. Acquir. Immune Defic. Syndr.. 2014;66(2):155-63.
Havers FP, Detrick B, Cardoso SW, et al. "Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS ONE. 2014;9(4):e95164.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Vogler MA, Smeaton LM, Wright RL, et al. "Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227." J. Acquir. Immune Defic. Syndr.. 2014;65(5):542-50.
Li JZ, Chapman B, Charlebois P, et al. "Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy." PLoS ONE. 2014;9(3):e90485.
Gupta SK, Kitch D, Tierney C, et al. "Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial." Open Forum Infect Dis. 2014;1(1):ofu003.
Wallis CL, Aga E, Ribaudo H, et al. "Drug susceptibility and resistance mutations after first-line failure in resource limited settings." Clin. Infect. Dis.. 2014;59(5):706-15.
Chew KW, Hua L, Bhattacharya D, et al. "The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection." Open Forum Infect Dis. 2014;1(3):ofu104.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Luetkemeyer AF, Kendall MA, Wu X, et al. "Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB." J. Clin. Microbiol.. 2014;52(4):1052-9.
Zheng L, Taiwo B, Gandhi RT, et al. "Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;67(2):153-60.
Hitti J, Halvas EK, Zheng L, et al. "Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207." J AIDS Clin Res. 2014;5(11).
Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.

Pages